Shukra Pharma Signs MoU With US Firm for AI Surgical Robotics in India
New Delhi: Shukra Pharmaceuticals Limited has entered into a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc., USA, for the introduction, promotion, and commercialisation of next-generation AI-enabled soft-tissue surgical robotic systems in India and select South Asian markets, the company informed the stock exchange through a regulatory filing.
As per the filing, the collaboration will cover India, Nepal, Bangladesh, Sri Lanka, Maldives, and Bhutan, subject to applicable regulatory approvals. The entire scope of work under the proposed collaboration will be executed through Shukra Robotics Pvt. Ltd., a subsidiary of Shukra Pharmaceuticals Limited.
Under the proposed association, the two parties intend to expand access to advanced robot-assisted minimally invasive soft-tissue surgeries by leveraging high-precision and stability-driven robotic platforms. The collaboration also aims to integrate artificial intelligence and digital surgery workflows to enable standardised procedure pathways and enhanced clinical efficiency.
In addition, the MoU focuses on strengthening regional healthcare infrastructure through technology transfer, clinician training, and scalable deployment models. While Borns Medical Robotics Inc. will contribute its expertise in surgical robotics platforms and AI-enabled technologies, Shukra Pharmaceuticals will leverage its established presence, regulatory execution capabilities, and healthcare market reach in India and South Asia.
The company stated that the proposed collaboration aligns with its long-term growth strategy of diversifying into high-value, technology-driven healthcare segments. The association is expected to enhance the company’s consolidated business portfolio, create new revenue opportunities through commercialisation and hospital partnerships, strengthen brand visibility in emerging digital healthcare solutions, and support long-term value creation for shareholders by participating in the rapidly growing global surgical robotics market.
Shukra Pharmaceuticals clarified that the MoU is non-binding in nature and only outlines the intent of the parties to explore definitive agreements in the future. Any such agreements will be subject to detailed commercial terms, mutual consent, and regulatory approvals. The filing also stated that there is no equity participation, shareholding arrangement, or monetary consideration involved at this stage, and the transaction does not fall under related-party transactions and is being undertaken at arm’s length.
